Discover the latest news and developments.


CellVax Selects Theragent as Manufacturing Partner for Phase 2 Clinical Trial for Prostate Cancer Immunotherapy

Theragent, a cell therapy Contract Development and Manufacturing Organization (CDMO) focused on advancing next-generation cancer and rare disease treatments, has announced that they have been selected by CellVax Therapeutics to provide manufacturing and testing services for CellVax’s novel cancer immunotherapy candidate FK-PC101 entering Phase 2 clinical trials. FK-PC101 is a cell-based autologous cancer vaccine for […]

Read More
Skip to toolbar